Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of ABBV-8E12 in early Alzheimer's disease
NL-OMON49765Phase 2Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of tilavonemab in Alzheimer's disease (AD) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Long-term safety and tolerability. Planned start May 2020; status: withdrawn.
02
Drugs
tilavonemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON49765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49765.